title: Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study.
abstract: BACKGROUND
  The effectiveness of high-protein (HP) diets in reducing body weight and adiposity and potentially improving clinical outcomes in heart failure (HF) is not known.
  
  
  OBJECTIVE
  This feasibility study was conducted to evaluate the impact of 3 dietary interventions on body weight and adiposity, functional status, lipid profiles, glycemic control, and quality of life (QOL) in overweight and obese patients with HF and type 2 diabetes mellitus.
  
  
  METHODS
  Fourteen patients with HF with a body mass index greater than 27 kg/m2 were randomized to an HP diet, a standard protein diet, or a conventional diet. Data were obtained at baseline and 12 weeks.
  
  
  RESULTS
  There were no significant differences in age (59 +/- 10 years), sex (78% male), New York Heart Association class (43% class II, 57% class III), and HF etiology or left ventricular ejection fraction (26 +/- 7) between the groups at baseline. Patients on the HP diet demonstrated significantly greater reductions in weight (P = .005), percent body fat (P = .036), total cholesterol (P = .016), triglyceride concentrations (P = .034), and low-density lipoprotein cholesterol (P = .041) and greater improvements in functional status (6-minute walk [P = .010] and VO2 peak [P = .003]), high-density lipoprotein cholesterol (P = .006), and physical QOL scores (P = .022) compared with those on standard protein and conventional diets.
  
  
  CONCLUSIONS
  A 12-week HP diet resulted in moderate weight loss and reduced adiposity in a small sample of overweight and obese patients with HF that were associated with improvements in functional status, lipid profiles, glycemic control, and QOL. However, these preliminary findings must be confirmed in studies with more participants and long-term follow-up.
authors.affiliation: School of Nursing, University of California, Los Angeles, CA 90095-6918, USA. levangel@ucla.edu
authors.forename: Lorraine S
authors.initials: LS
authors.lastname: Evangelista
authors.forename: David
authors.initials: D
authors.lastname: Heber
authors.forename: Zhaoping
authors.initials: Z
authors.lastname: Li
authors.forename: Susan
authors.initials: S
authors.lastname: Bowerman
authors.forename: Michele A
authors.initials: MA
authors.lastname: Hamilton
authors.forename: Gregg C
authors.initials: GC
authors.lastname: Fonarow
mesh_terms: D000203:Activities of Daily Living; D050154:Adiposity; D000368:Aged; D000704:Analysis of Variance; D001294:Attitude to Health; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D004044:Dietary Proteins / Q000008:administration & dosage*; D005080:Exercise Test; D005240:Feasibility Studies; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000178:diet therapy* / Q000523:psychology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control*; D011788:Quality of Life / Q000523:psychology*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D004044:Dietary Proteins